During the last decades, advances in anti-myeloma therapeutics, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies have considerably improved the treatment outcome in myeloma [2]. This evidence concerns the gene CD38 and plasma cell myeloma.